# PT-141 Research: The Bremelanotide Evidence Record, Cited

> PT-141 research, read straight: the preclinical mechanism work, the RECONNECT Phase 3 trials, the human fMRI evidence, and the FDA label, each cited to source.

From the founding melanocortin pharmacology to the RECONNECT Phase 3 trials and the FDA label — every finding logged to its source.

## The short version

The **PT-141 research** record is unusually complete for a peptide discussed online: it runs from animal pharmacology in the early 2000s to two large human trials and an FDA approval in 2019 [7][10]. The early work showed PT-141 acts in the brain to drive sexual behavior in rats and monkeys [1] and the appetitive (wanting) side of behavior in female rats [2]. The big human trials (called RECONNECT) then showed a real but modest benefit for desire in women with HSDD [3], which held up over a year [4].

Newer work fills in the picture: brain-imaging studies show where the effect happens [5], and a 2025 animal study refines which brain circuits are and aren't involved [6]. This page walks the record in order — preclinical, then the human trials, then the label, then the newest data — and cites every finding so you can check it on [PT-141 references](/references).

## Founding pharmacology: a central mechanism

PT-141 entered the literature as a melanocortin agonist for sexual dysfunction. The foundational paper established that PT-141, a synthetic alpha-MSH analogue, agonizes MC3R/MC4R expressed mainly in the CNS; systemic administration produced penile erections in rats and nonhuman primates, activated hypothalamic neurons (increased c-Fos), and produced rapid dose-dependent erectile activity in men with erectile dysfunction [1].

The female-behavior work followed. In female rats, PT-141 selectively stimulated appetitive solicitational sexual behaviors without affecting lordosis, pacing, or general motor activity — the first reported pharmacological agent acting specifically on appetitive female sexual behavior [2]. Together these studies fixed PT-141 as a central, not peripheral, actor.

## The RECONNECT Phase 3 trials

The pivotal evidence is two identical Phase 3 randomized controlled trials, RECONNECT (n=1267 premenopausal women with HSDD) [3]. Bremelanotide 1.75 mg subcutaneous as-needed produced a statistically significant improvement in sexual desire (integrated FSFI-desire +0.35, P<.001) and a reduction in desire-related distress (FSDS-DAO item 13 −0.33, P<.001) versus placebo over 24 weeks; both coprimary endpoints were met in both trials [3]. The most common adverse events were nausea, flushing, and headache [3].

Durability came from the 52-week open-label extension (684 women): no new safety signals, sustained desire improvement, with nausea (40.4%), flushing (20.6%), and headache (12.0%) the most common drug-related treatment-emergent events [4].

## Direct neuroimaging and a refining 2025 study

The mechanism has direct human-brain support. A randomized, double-blind, placebo-controlled crossover fMRI study of 31 premenopausal women with HSDD found MC4R agonism significantly increased sexual desire for up to 24 hours and altered task-based brain processing — enhanced amygdala–insula functional connectivity and cerebellar/supplementary-motor activity — in response to erotic stimuli [5].

A 2025 study in female Syrian hamsters refined the circuit map: MC3R/MC4R mRNA was concentrated in ventral-tegmental-area dopamine neurons, but neither low- nor high-dose bremelanotide changed melanocortin-receptor mRNA in the mesolimbic dopamine system, and bremelanotide did not enhance sexual reward (conditioned place preference) — suggesting it does not act on the VTA–nucleus-accumbens reward circuit [6]. A negative, clarifying result of this kind is part of an honest record.

## The regulatory and review record

The authoritative dose, pharmacokinetics, and warnings come from the US prescribing information for bremelanotide injection: the HSDD indication, 1.75 mg subcutaneous as-needed (max one dose/24 h, no more than eight doses/month), terminal half-life ~2.7 h, and a transient blood-pressure warning with a hypertension/CVD contraindication [7]. The first-approval review documents the June 2019 milestone and development history [10], and a 2020 analysis of FDA-approved peptide and oligonucleotide therapeutics situates bremelanotide within that year's strong run of peptide approvals [9]. An early development profile records PT-141's intranasal ED origins and planned Phase III [8], a narrative HSDD review positions melanocortins as excitatory neuromodulators of desire distinct from serotonergic mechanisms [11], and a forensic study confirms bremelanotide in seized black-market samples — a reminder that unregulated supply circulates outside all of this [13].

---

A spectrometer-style readout of the PT-141 (bremelanotide) record — every value logged to its source and marked in-spec or contested, the lone 2019 approval for premenopausal HSDD calibrated against every off-label and research-chemical use that sits outside its band; no clinic behind the instrument and nothing here prescribed, dosed, or sold.